Tezepelumab helps severe asthma patients reduce oral steroids over 28 weeks

MedicalXpress | Mai 30, 2026

New results from the Phase III SUNRISE clinical trial show that tezepelumab significantly reduced the need for long-term oral corticosteroid use in adults with severe oral corticosteroid-dependent asthma while maintaining asthma control and improving key clinical outcomes. The findings were published in The Lancet Respiratory Medicine.